Fallopian Tube Cancer, Fallopian Tube Infection
Conditions
Brief summary
This study will evaluate the impact of low dose aspirin on normal fallopian tube fimbriae in women who have surgery to have their fallopian tubes removed. Participants will take a low dose of aspirin for 2 weeks before their surgery. A portion of the removed fallopian tubes will also be collected for future research and routine pathology purposes.
Detailed description
Subjects in this study will receive low dose aspirin for 14 days before undergoing surgery to remove fallopian tubes removed to determine whether aspirin decreases inflammation in the fallopian tube. Subjects will also submit blood samples at their initial visit with their oncologist, at the time of surgery and at the pre-operative visit to measure inflammation markers and blood counts. A portion of the subject's fallopian tube will be collected for future research studies.
Interventions
DRUGAspirin 81 mg
Subjects will take aspirin daily for 14 days leading up to surgery to determine whether it impacts inflammation of fallopian tubes.
Sponsors
University of Oklahoma
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Women undergoing gynecologic surgery for presumed benign indications that includes the removal of their fallopian tubes. This may include sterilization procedures, hysterectomy or partial or full adnexectomy. * Eligible women will have fulfilled their childbearing desires * Age \> 21 Considered low risk for prevalent fallopian tube cancer (not undergoing risk reducing surgery for a known BRCA mutation or other known hereditary predisposition syndrome, family history of ovarian cancer in a first degree relative.
Exclusion criteria
* Males * Women who have presumed or known gynecologic cancer * Women less than 21 years of age * Women currently on either regular aspirin therapy, non-steroidal anti-inflammatory drugs (NSAIDS), acetaminophen or chronic steroidal anti-inflammatory medications. * Women with known bleeding diathesis or bleeding disorder. * Women who do not consent for removal of both fallopian tubes. * Women with a history of gastritis or peptic ulcer disease requiring treatment. (Patients with a history of occasional H1 or H2 blocker use for gastro esophageal reflux disease are NOT excluded). * Women with reported aspirin or NSAID allergy * Women with asthma and/or nasal polyps
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects who exhibited alterations in the fallopian tube immune microenvironment | 5 years | Immuno-cellular assays and percentages of specific immune cells will be compared to control tissue samples. |
| Number of subjects who exhibited less carcinogenic potential than control specimens | 5 years | Ciliate cells from specimens will be isolated and the number of colony forming units will be compared to control samples. |
| Number of subjects who exhibited changes in transcriptome profile compared to control specimens | 5 years | Normal fallopian tube fibria will be compared to ovarian cancer specimens to identify novel biomarkers for diagnosis, targets for prevention and better treatment strategies. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORLaura Holman
Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Outcome results
None listed